AWIQLI 2100 UNIT / 3 ML — DIN 02546221
INSULIN ICODEC : 2100 UNIT / 3 ML · NOVO NORDISK CANADA INC · SOLUTION · wholesale supply in Canada
Health Canada status: MARKETED
What is AWIQLI?
AWIQLI 2100 UNIT / 3 ML contains INSULIN ICODEC : 2100 UNIT / 3 ML. It is listed in the Health Canada Drug Product Database under DIN 02546221, held by NOVO NORDISK CANADA INC, supplied as SOLUTION for SUBCUTANEOUS administration. Health Canada currently lists it as marketed, status dated 13-Jun-2024. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
What is AWIQLI used for?
AWIQLI® (insulin icodec injection) is indicated for the once-weekly treatment of adults with diabetes mellitus to improve glycemic control. In type 2 diabetes, AWIQLI® may be used along with tablets or injections for diabetes - including short or rapid-acting insulins. In type 1 diabetes, AWIQLI® must always be used along with short or rapid-acting insulins.
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
How much does Insulin Icodec cost around the world?
Insulin Icodec is listed on 3 of the national price registers Nexara ingests. Each country publishes on a different basis, so those figures are not comparable with one another — or with a Canadian wholesale price.
What a market publishes matters more than the number it publishes. Greece publishes a producer price (ex-factory); Norway publishes a max AUP (pharmacy retail); South Africa publishes a single exit price. Comparing an ex-factory ceiling against a pharmacy public price tells you nothing about either, and comparing either against a Canadian landed cost tells you less.
| Market | Price basis published there | Brands | Packs listed | Range |
|---|---|---|---|---|
| Greece | producer price (ex-factory) | 41 | 41 | EUR███.██ |
| Norway | max AUP (pharmacy retail) | 5 | 6 | NOK███.██ |
| South Africa | single exit price | 1 | 2 | ZAR███.██ |
49 pack listings across 47 brand entries and 3 price bases, refreshed 07 Sep 2026. Ranges span every Insulin Icodec pack in that market, so a high figure is usually a larger pack rather than the same product.
Canada publishes no comparable public list price. For a delivered Canadian price on a licensed account, verify your licence — it takes about a minute.
Is there a generic Insulin Icodec in Canada, and who makes it?
Every market authorization holder with a Canadian DIN for this molecule, and how many of their listings Health Canada currently shows as marketed.
Only one market authorization holder has a Canadian DIN containing Insulin Icodec — 3 DINs, of which 3 are currently marketed. There is no second Canadian source today, so a supply interruption on this holder has no domestic substitute at the same molecule.
| Market authorization holder | DINs | Marketed | Brand names | Position |
|---|---|---|---|---|
| NOVO NORDISK CANADA INC | 3 | 3 | AWIQLI | Sourceable in Canada |
Health Canada’s Drug Product Database does not flag which listing is the originator and which are subsequent-entry products, so Nexara does not label them here. Interchangeability is determined provincially, not federally — confirm for your province before a formulary switch. Nexara can confirm which of these is actually obtainable, and on what lead time, per order.
How is it supplied and stored?
Pack configuration, storage class and the handling constraints that drive cold-chain planning. One DIN can cover more than one pack size, and the pack — not the DIN — is what gets priced, shipped and invoiced.
| Strength on the label | 2100 UNIT / 3 ML |
|---|---|
| Dosage form | SOLUTION |
| Route | SUBCUTANEOUS |
| Pack configuration (monograph) | Solution for Injection in the FlexTouch® pre-filled pen, 700 units/mL. Available in 1 mL (700 units), 1.5 mL (1050 units), and 3 mL (2100 units) pre-filled pens. Pack size of 1 pen/pack. The 1.0 mL pen is only available as a Sample pack. Packaging consists of a cartridge (Type I glass) with a plunger (halobutyl) and a laminated rubber sheet (halobutyl/polyisoprene) contained in a pre-filled multidose disposable pen made of polypropylene, polyoxymethylene, polycarbonate and acrylonitrile butadiene styrene. |
| Storage | Recommended Storage: Dispense in the original sealed carton with the enclosed Instructions for Use. Do not store in the freezer or directly adjacent to the refrigerator cooling element. Do not freeze. Do not use AWIQLI® if it has been frozen. Before first use: Store in a refrigerator (2 °C to 8 °C). Keep away from the freezing element. Keep the cap on the pen in order to protect it from light. After first opening or if carried as a spare: You can carry your AWIQLI® pre-filled pen (FlexTouch®) with you and keep it at room temperature (below 30 °C) or in a refrigerator (2 °C to 8 °C) for up to 12 weeks. Always keep the cap on the pen when you are not using it in order to protect it from light. Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. Keep out of reach and sight of children. Do not leave the pen in a car or other place where it can get too hot or too cold. Avoid exposing AWIQLI® to direct sunlight. Keep AWIQLI® away from heat, microwaves and out of the light. Do not drop your pen or knock it against hard surfaces. Do not try to repair your pen or pull it apart. Do not expose your pen to dust, dirt, or liquid. Do not wash, soak, or lubricate your pen. If necessary, it may be cleaned with a mild detergent on a moistened cloth. |
| Shipping class | Cold chain — validated shipper with temperature monitoring |
Before an order line is unambiguous Nexara needs the strength, the pack size and the presentation, because this listing covers more than one of them.
Cold chain. This product is stored refrigerated. Nexara ships it on a validated cold chain with temperature monitoring; a delivery address that cannot receive and store it at 2–8 °C on arrival must be flagged before the order is placed.
Substance and classification
| Active substance | Insulin Icodec |
|---|---|
| ATC code | A10AE07 |
| Biosimilar biologic | No |
Health Canada record and identifiers
The regulatory facts straight from the Drug Product Database, plus every identifier form Nexara accepts on a purchase order. A DIN written without its leading zeros is the commonest reason an order line fails to match.
| DIN (8-digit, as used in ordering) | 02546221 |
|---|---|
| DIN (unpadded, as printed on some documents) | 2546221 |
| Brand name | AWIQLI |
| Generic / active ingredient | INSULIN ICODEC : 2100 UNIT / 3 ML |
| Market authorization holder | NOVO NORDISK CANADA INC |
| Health Canada schedule | Schedule D |
| ATC code | A10AE07 |
| ATC anatomical main group | A — Alimentary tract and metabolism |
| ATC therapeutic subgroup | A10AE |
| Current status | MARKETED |
| Status date | 13-Jun-2024 |
| Status source | Live Health Canada DPD sync |
Verify on the primary sources
How is it administered?
AWIQLI® is available as a single-patient use FlexTouch® pen. The pre-filled FlexTouch® pen delivers doses in 10 units increments and can deliver up to 700 units in a single injection. Inject AWIQLI® subcutaneously once-weekly on any day of the week but preferably the same day each week. It may be administered at any time during the day. Individualize and titrate the dose of AWIQLI® based on the patient's metabolic needs, blood glucose monitoring results, and glycemic control goal. The potency of insulin analogues, including insulin icodec is expressed in units (U). One (1) unit (U) of insulin icodec corresponds to 1 international unit (IU) of human insulin. Dose adjustments may be needed with changes in renal or hepatic function or during illness to minimize the risk of hypoglycemia or hyperglycemia. Due to the long half-life of insulin icodec, adjustment of dose is not advised during acute illness nor if patients make short-term changes in their physical activity level or usual diet. In patients with type 2 diabetes mellitus, AWIQLI® can be used in combination with oral antidiabetic agents (OADs). In patients with type 1 diabetes, AWIQLI® must be used in regimens containing rapid-acting or short-acting insulin to cover mealtime insulin requirements. Blood glucose monitoring is recommended for all patients with diabetes. AWIQLI® must not be used for the treatment of diabetic ketoacidosis. AWIQLI® must not be administered via intravenous infusion or intramuscular injection. When switching from previous daily basal insulin to once weekly AWIQLI®, close glucose monitoring is recommended. The first weekly dose of AWIQLI® should be taken on the day following the last dose of once- or twice-daily basal insulin. When switching patients from once- or twice-daily basal insulin, the corresponding weekly AWIQLI® dose is the previous daily basal insulin dose multiplied by 7, rounded to the nearest 10 units. Subsequent doses can be titrated based on metabolic needs, blood glucose monitoring results, and glycemic control goal. For patients requiring a one-time additional dose (Week 1 only), 1.5 x (previous daily basal insulin dose x 7), rounded to the nearest 10 units, may be administered. The one-time additional dose must not be added for the second injection onwards. The second once-weekly dose of AWIQLI® is the total daily basal dose multiplied by 7, rounded to the nearest 10 units. The third and subsequent doses can be titrated based on the patient's metabolic needs, blood glucose monitoring results, and glycemic control goal. If a dose is missed, it is recommended that it is administered as soon as possible. Patients can resume dosing on their regular dosing day as long as there are minimum 4 days between two consecutive doses, otherwise patients must be instructed to continue their dosing once weekly on the new day. Monitoring of fasting blood glucose is recommended. Inject AWIQLI® subcutaneously into the thigh, upper arm, or abdomen. Rotate injection sites within the same region from one injection to the next to reduce the risk of lipodystrophy and localized cutaneous amyloidosis. Do not inject into areas of lipodystrophy or localized cutaneous amyloidosis. During changes to a patient's insulin regimen, increase the frequency of blood glucose monitoring. Use AWIQLI® pen with caution in patients with visual impairment that may rely on audible clicks to dial their dose. DO NOT administer AWIQLI® intramuscularly, intravenously or in an insulin infusion pump. DO NOT dilute or mix AWIQLI® with any other insulin or solution. DO NOT transfer AWIQLI® from the AWIQLI® pen into a syringe for administration.
Included because it drives pack selection and wastage. Consult the monograph.
Contraindications
AWIQLI® is contraindicated during episodes of hypoglycemia. It is also contraindicated in patients who are hypersensitive to this drug or to any ingredient in the formulation, including any non-medicinal ingredient, or component of the container. AWIQLI® should not be used in patients with a history of hypoglycemia unawareness. AWIQLI® must not be used in combination with other long-acting (basal) insulins (e.g., insulin detemir, insulin glargine, or insulin degludec).
Warnings and precautions
Hypoglycemia is the most common adverse effect of insulin products including AWIQLI®. As with all insulin products the timing of hypoglycemia may differ. Glucose monitoring shall be performed for all patients with diabetes mellitus treated with insulin. Uncorrected hypoglycemic or hyperglycemic reactions can cause loss of consciousness, coma, and, or death. Switching a patient between another type, brand or manufacturer of insulin and AWIQLI® should be done under medical supervision and may result in the need for a change in dosage. Changes in insulin regimen from other insulins to AWIQLI® may result in increased risk of hypoglycemia or hyperglycemia. AWIQLI® must not be administered more frequently than once a week. Medication errors have been reported in which patients accidentally administer short-acting insulin instead of basal (long-acting) insulin. Specific attention should be paid when switching from a daily basal insulin to AWIQLI®, which is administered weekly. Inspect AWIQLI® visually prior to administration and use only if the solution appears clear and colourless. Never mix AWIQLI® with any other insulin. AWIQLI® must not be used in combination with other long-acting (basal) insulins (e.g., insulin detemir, insulin glargine, or insulin degludec). Never administer AWIQLI® by intramuscular (IM) injection, intravenously (IV), or with an insulin infusion pump. Never Share a AWIQLI® FlexTouch® Pen, or Needle Between Patients. Sharing poses a risk for transmission of blood-borne pathogens. Stress or concomitant illness, especially infectious and febrile conditions, may change insulin requirements. The early warning symptoms of hypoglycemia may be changed, be less pronounced, or absent when transferring to AWIQLI®. Risk of hypoglycemia is increased on Days 2-4 of the weekly AWIQLI® dosing cycle. Patients who are blind or have poor vision must be instructed to always get help/assistance from another person who has good vision and is trained in using the pre-filled pen. To avoid dosing errors and potential overdose, patients and healthcare professionals should never use a syringe to draw the medicinal product from the cartridge in the pre-filled pen. Thiazolidinediones (TZDs) in combination with insulin can cause dose related fluid retention, which may lead to or exacerbate congestive heart failure. Patients treated with insulin, including AWIQLI® and a PPAR-gamma agonist should be observed for signs and symptoms of congestive heart failure. If congestive heart failure develops, it should be managed according to current standards of care and discontinuation or dose reduction of the PPAR-gamma agonist must be considered. The patient's ability to concentrate and react may be impaired as a result of hypoglycemia or hyperglycemia or, for example, as a result of visual impairment. This may constitute a risk in situations where these abilities are of special importance (e.g., driving a car or operating machinery). Patients should be advised to take precautions to avoid hypoglycemia while driving. This is particularly important in those who have reduced or absent awareness of the warning symptoms of hypoglycemia or have frequent episodes of hypoglycemia. It should be considered whether it is advisable to drive or operate machinery in these circumstances. Changes in an insulin regimen (e.g., insulin strength, manufacturer, type, injection site or method of administration) may affect glycemic control and predispose to hypoglycemia or hyperglycemia. Make any changes to a patient's insulin regimen under close medical supervision with increased frequency of blood glucose monitoring. Severe hypoglycemia can cause seizures, may be life-threatening or cause death. Prolonged or severe hypoglycemic attacks, especially if recurrent, may lead to neurological damage, loss of consciousness, coma, or death. As with all insulins, additional caution (including intensified blood glucose monitoring) should be exercised in patient populations who are
What can be used instead?
Alternatives on every axis a buyer actually considers — the same molecule in another presentation, the same class, an adjacent class, or a fixed-dose combination. Every row is led by the marketed DIN count, because that is what can be bought this week.
1 · Same molecule, other Canadian presentations
3 of 3 Canadian DINs for this molecule are currently marketed. Marketed products are listed first.
| Product | Strength | Form | Holder | Health Canada status | DIN |
|---|---|---|---|---|---|
| AWIQLI | 700 UNIT | SOLUTION | NOVO NORDISK CANADA INC | MARKETED | 02546205 |
| AWIQLI | 1050 UNIT / 1.5 ML | SOLUTION | NOVO NORDISK CANADA INC | MARKETED | 02546213 |
2 · Same class — other molecules in ATC A10AE
| Molecule | Canadian brands | DINs | Marketed | Sourceable |
|---|---|---|---|---|
| Insulin Glargine | BASAGLAR · LANTUS · SEMGLEE · TOUJEO DOUBLESTAR · +1 more | 11 | 8 | Yes |
| Insulin Icodec | AWIQLI | 3 | 3 | Yes |
| Insulin Degludec | TRESIBA | 3 | 3 | Yes |
| Insulin Glargine And Lixisenatide | SOLIQUA | 1 | 1 | Yes |
| Insulin Detemir | LEVEMIR FLEXTOUCH · LEVEMIR PENFILL | 2 | 0 | Not in Canada |
| Insulin (Human) | HUMULIN-U ULTRALENTE INJ 100UNIT/ML · NOVOLIN GE ULTRALENTE INJ SUS 100U/ML | 2 | 0 | Not in Canada |
| Insulin Degludec And Liraglutide | XULTOPHY | 1 | 0 | Not in Canada |
A molecule with zero marketed DINs cannot be sourced domestically, however many approvals it holds — if one of these sits on a formulary or in an older protocol, that is the line to check.
3 · Adjacent classes in ATC A10A
| ATC subgroup | Molecules | DINs | Marketed |
|---|---|---|---|
| A10AB | Insulin (Beef) · Insulin (Human) · Insulin (Pork) · Insulin Aspart · Insulin Glulisine · +1 more | 40 | 24 |
| A10AD | Insulin (Human) · Insulin Aspart · Insulin Lispro | 31 | 9 |
| A10AC | Insulin (Human) · Insulin (Pork) | 13 | 5 |
Not clinical advice. These tables describe what can be supplied in Canada, not what should be prescribed. Substitution within or across classes is a prescriber and pharmacist decision, and interchangeability is determined provincially.
What else is AWIQLI called?
Also recorded in Canada as: INSULIN ICODEC-ABAE (US), Insulin icodec (GLOBAL), Insulin icodec (US), Insulin icodec (UK).
The same molecule, Insulin Icodec, is registered under other names elsewhere. Buyers and prescribers searching from outside Canada — or working from a foreign prescription or tender document — often know it by one of these:
| Name | Script | Registered in |
|---|---|---|
| Actrapid HM (ge) | Latin | South Africa |
| Insuman Rapid | Latin | Norway |
| Humulin NPH | Latin | Norway |
| Humulin NPH KwikPen | Latin | Norway |
| Insuman Infusat | Latin | Norway |
Names are taken from national medicine registers and published price lists. A product registered abroad is not authorized for sale in Canada unless it holds its own DIN; import is possible only through the routes Health Canada permits.
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address. Patients and unlicensed buyers are routed to a partner pharmacy.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Why is there no price on this page?
Nexara quotes a delivered Canadian price per order, against a verified licence. Foreign list prices are published on incompatible bases and are not a guide to what any buyer can obtain here, so this page shows which markets list the molecule and on what basis, and nothing more.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.